vs
Side-by-side financial comparison of Insulet Corporation (PODD) and Root, Inc. (ROOT). Click either name above to swap in a different company.
Insulet Corporation is the larger business by last-quarter revenue ($783.7M vs $397.0M, roughly 2.0× Root, Inc.). On growth, Insulet Corporation posted the faster year-over-year revenue change (31.2% vs 21.5%). Over the past eight quarters, Insulet Corporation's revenue compounded faster (33.2% CAGR vs 24.8%).
An insulin pump is a medical device used for the administration of insulin in the treatment of diabetes mellitus, also known as continuous subcutaneous insulin therapy . The device configuration may vary depending on design. A traditional pump includes:the pump a disposable reservoir for insulin a disposable infusion set, including a cannula for subcutaneous insertion and a tubing system to connect the insulin reservoir to the cannula.
Root Insurance Company is an online car insurance company operating in the United States.
PODD vs ROOT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $783.7M | $397.0M |
| Net Profit | $101.6M | — |
| Gross Margin | 72.6% | — |
| Operating Margin | 18.7% | 2.6% |
| Net Margin | 13.0% | — |
| Revenue YoY | 31.2% | 21.5% |
| Net Profit YoY | 0.9% | — |
| EPS (diluted) | $1.42 | $0.35 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $783.7M | $397.0M | ||
| Q3 25 | $706.3M | $387.8M | ||
| Q2 25 | $649.1M | $382.9M | ||
| Q1 25 | $569.0M | $349.4M | ||
| Q4 24 | $597.5M | $326.7M | ||
| Q3 24 | $543.9M | $305.7M | ||
| Q2 24 | $488.5M | $289.2M | ||
| Q1 24 | $441.7M | $254.9M |
| Q4 25 | $101.6M | — | ||
| Q3 25 | $87.6M | $-5.4M | ||
| Q2 25 | $22.5M | $22.0M | ||
| Q1 25 | $35.4M | $18.4M | ||
| Q4 24 | $100.7M | — | ||
| Q3 24 | $77.5M | $22.8M | ||
| Q2 24 | $188.6M | $-7.8M | ||
| Q1 24 | $51.5M | $-6.2M |
| Q4 25 | 72.6% | — | ||
| Q3 25 | 72.2% | — | ||
| Q2 25 | 69.7% | — | ||
| Q1 25 | 71.9% | — | ||
| Q4 24 | 72.1% | — | ||
| Q3 24 | 69.3% | — | ||
| Q2 24 | 67.7% | — | ||
| Q1 24 | 69.5% | — |
| Q4 25 | 18.7% | 2.6% | ||
| Q3 25 | 16.7% | 0.1% | ||
| Q2 25 | 18.7% | 7.1% | ||
| Q1 25 | 15.6% | 6.8% | ||
| Q4 24 | 18.3% | 10.7% | ||
| Q3 24 | 16.2% | 11.3% | ||
| Q2 24 | 11.2% | 1.3% | ||
| Q1 24 | 12.9% | 2.1% |
| Q4 25 | 13.0% | — | ||
| Q3 25 | 12.4% | -1.4% | ||
| Q2 25 | 3.5% | 5.7% | ||
| Q1 25 | 6.2% | 5.3% | ||
| Q4 24 | 16.9% | — | ||
| Q3 24 | 14.2% | 7.5% | ||
| Q2 24 | 38.6% | -2.7% | ||
| Q1 24 | 11.7% | -2.4% |
| Q4 25 | $1.42 | $0.35 | ||
| Q3 25 | $1.24 | $-0.35 | ||
| Q2 25 | $0.32 | $1.29 | ||
| Q1 25 | $0.50 | $1.07 | ||
| Q4 24 | $1.38 | $1.42 | ||
| Q3 24 | $1.08 | $1.35 | ||
| Q2 24 | $2.59 | $-0.52 | ||
| Q1 24 | $0.73 | $-0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $669.3M |
| Total DebtLower is stronger | $930.8M | $200.3M |
| Stockholders' EquityBook value | $1.5B | $284.3M |
| Total Assets | $3.2B | $1.7B |
| Debt / EquityLower = less leverage | 0.61× | 0.70× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $669.3M | ||
| Q3 25 | — | $653.3M | ||
| Q2 25 | — | $641.4M | ||
| Q1 25 | — | $609.4M | ||
| Q4 24 | — | $599.3M | ||
| Q3 24 | — | $674.8M | ||
| Q2 24 | — | $667.2M | ||
| Q1 24 | — | $640.5M |
| Q4 25 | $930.8M | $200.3M | ||
| Q3 25 | $934.9M | $200.4M | ||
| Q2 25 | $939.0M | $200.1M | ||
| Q1 25 | $1.6B | $200.0M | ||
| Q4 24 | $1.3B | $200.1M | ||
| Q3 24 | $1.4B | $300.9M | ||
| Q2 24 | $1.4B | $300.1M | ||
| Q1 24 | $1.4B | $299.3M |
| Q4 25 | $1.5B | $284.3M | ||
| Q3 25 | $1.4B | $265.0M | ||
| Q2 25 | $1.5B | $244.5M | ||
| Q1 25 | $1.3B | $228.7M | ||
| Q4 24 | $1.2B | $203.7M | ||
| Q3 24 | $1.1B | $181.9M | ||
| Q2 24 | $998.4M | $151.3M | ||
| Q1 24 | $790.7M | $165.7M |
| Q4 25 | $3.2B | $1.7B | ||
| Q3 25 | $3.0B | $1.6B | ||
| Q2 25 | $3.5B | $1.6B | ||
| Q1 25 | $3.5B | $1.6B | ||
| Q4 24 | $3.1B | $1.5B | ||
| Q3 24 | $3.0B | $1.6B | ||
| Q2 24 | $2.9B | $1.5B | ||
| Q1 24 | $2.6B | $1.4B |
| Q4 25 | 0.61× | 0.70× | ||
| Q3 25 | 0.68× | 0.76× | ||
| Q2 25 | 0.64× | 0.82× | ||
| Q1 25 | 1.21× | 0.87× | ||
| Q4 24 | 1.07× | 0.98× | ||
| Q3 24 | 1.21× | 1.65× | ||
| Q2 24 | 1.36× | 1.98× | ||
| Q1 24 | 1.72× | 1.81× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $183.3M | $206.5M |
| Free Cash FlowOCF − Capex | $48.2M | — |
| FCF MarginFCF / Revenue | 6.2% | — |
| Capex IntensityCapex / Revenue | 17.2% | 0.0% |
| Cash ConversionOCF / Net Profit | 1.80× | — |
| TTM Free Cash FlowTrailing 4 quarters | $377.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $183.3M | $206.5M | ||
| Q3 25 | $125.7M | $57.6M | ||
| Q2 25 | $196.5M | $52.0M | ||
| Q1 25 | $63.8M | $26.8M | ||
| Q4 24 | $147.7M | $195.7M | ||
| Q3 24 | $98.5M | $49.4M | ||
| Q2 24 | $96.5M | $62.6M | ||
| Q1 24 | $87.6M | $14.5M |
| Q4 25 | $48.2M | — | ||
| Q3 25 | $100.1M | — | ||
| Q2 25 | $177.9M | — | ||
| Q1 25 | $51.5M | — | ||
| Q4 24 | $94.1M | $195.3M | ||
| Q3 24 | $71.8M | — | ||
| Q2 24 | $74.0M | $62.4M | ||
| Q1 24 | $65.5M | $14.3M |
| Q4 25 | 6.2% | — | ||
| Q3 25 | 14.2% | — | ||
| Q2 25 | 27.4% | — | ||
| Q1 25 | 9.1% | — | ||
| Q4 24 | 15.7% | 59.8% | ||
| Q3 24 | 13.2% | — | ||
| Q2 24 | 15.1% | 21.6% | ||
| Q1 24 | 14.8% | 5.6% |
| Q4 25 | 17.2% | 0.0% | ||
| Q3 25 | 3.6% | 0.0% | ||
| Q2 25 | 2.9% | 0.0% | ||
| Q1 25 | 2.2% | 0.0% | ||
| Q4 24 | 9.0% | 0.1% | ||
| Q3 24 | 4.9% | 0.0% | ||
| Q2 24 | 4.6% | 0.1% | ||
| Q1 24 | 5.0% | 0.1% |
| Q4 25 | 1.80× | — | ||
| Q3 25 | 1.43× | — | ||
| Q2 25 | 8.73× | 2.36× | ||
| Q1 25 | 1.80× | 1.46× | ||
| Q4 24 | 1.47× | — | ||
| Q3 24 | 1.27× | 2.17× | ||
| Q2 24 | 0.51× | — | ||
| Q1 24 | 1.70× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PODD
| U.S.Omnipod | $567.8M | 72% |
| International Omnipod | $214.0M | 27% |
| Drug Delivery | $1.9M | 0% |
ROOT
Segment breakdown not available.
